The COVID-19 Pandemic has exposed the imbalance between the Molecular Diagnostic infrastructure capacity & Demand driven by the Pandemic , Genomez a Project that was born at MIT COVID-19 Beat The Pandemic Hackathon under the Name COVID-19 Trace Coin with building PCR testing Capacity has Designed a PCR Test that integrates Data science powered by Artificial Intelligence, Machine Learning Technologies to multiply capacity of existing molecular laboratory infrastructure.|
The concept of Pooling Test Strategy did not achieve its true potential due to false positive results when a one positive masks the true negative samples with positive interpretation which mandates second run of pooling or individual testing, Known as Reopening of Positive Pool Groups which is a challenge to molecular diagnostic setup due to limited resources of skilled personnel and the 2nd challenge to recall individuals pf positive pool for retest. |
The last ten years of lab automation set the stage for an innovative solution developed by Genomez Team using AI, ML Technologies with which it became possible to tune Pooling Test Strategies as a response to MIT Call for Pooling Test innovation which is based on datasets increasing lab testing productivity increasing capacity from 5 up to 30 folds with same infrastructure. |
Our Proposed solution uses 3 elements combined of AI , ML algorithms to dynamically design pooling strategy with Zero False Positive and No false Negative where a test is sensitive enough in detecting Minimum infective LODs and maintaining Specificity of the Molecular Diagnostic Technology.|
Such an Innovation extends Beyond COVID-19 to other Infectious Diseases with major impact on Tuberculosis Screening , Sepsis Diagnosis and Cancer Screening Programs using Liquid Biopsies.|
Building am innovative solution to maximize lab capacity multiplier requires the use of the most advanced technologies to capitalize on networking effect thus using decentralized SaaS Model with plug and play functionality transform any lab from 1x to up to 30x in just seconds away with a click of a button to internet connectivity, this business model makes the solution exponentially scalable and versatile based on its modular nature without dependence on intermediaries for transactional fulfilment nor for payment collection each run can reduce cost by 80-90% against small that has ROI in Saving exceeding 25600%.|
Welcome To Genomez The PCR industry Re-Wired!
About Medical Diagnostic Assays is a Saudi Company that invests in companies changing the Gold Standards of the IVD Industry from Sepsis Diagnosis to Pooling Strategy it operates through sister companies in Six countries in North America , Europe & Asia